IQVIA Tops Everest Group’s 2026 Pharmaceutical Tech Rankings
Event summary
- IQVIA ranked No. 1 in Everest Group’s 2026 'Top 50 Pharmaceutical Technology Providers' report with a score of 96.8 out of 100.
- IQVIA is the only provider with technology coverage across all six pharmaceutical value-chain areas: drug discovery, clinical development, manufacturing, sales/marketing, supply chain, and pharmacovigilance.
- The ranking highlights IQVIA’s ability to integrate solutions across the product lifecycle, leveraging proprietary data, AI, and deep life sciences expertise.
The big picture
IQVIA’s top ranking underscores the industry shift toward end-to-end technology solutions in pharmaceuticals, where fragmented tools are being replaced by integrated platforms. The company’s emphasis on AI and privacy aligns with biopharma’s push for data-driven decision-making in tightly regulated markets. With 94,000 employees across 100 countries, IQVIA’s scale positions it as a dominant force in shaping the future of pharmaceutical technology.
What we're watching
- Competitive Differentiation
- Whether IQVIA’s full value-chain coverage can sustain its lead as biopharma demand for integrated solutions grows.
- AI Scalability
- The pace at which IQVIA scales its Healthcare-grade AI® capabilities across highly regulated environments.
- Market Expansion
- How IQVIA leverages this ranking to penetrate new geographies or customer segments.
Related topics